FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Xencor's Free Cash Flow for the
three
months ended in Mar. 2024 was $-56.3 Mil. Xencor's Revenue for the
three
months ended in Mar. 2024 was $12.8 Mil. Therefore, Xencor's FCF Margin % for the quarter that ended in Mar. 2024 was -439.82%.
The historical rank and industry rank for Xencor's FCF Margin % or its related term are showing as below:
XNCR'
s FCF Margin % Range Over the Past 10 Years
Min: -248.28 Med: -11.72 Max: 84.6
Current: 30.43
During the past 13 years, the highest FCF Margin % of Xencor was 84.60%. The lowest was -248.28%. And the median was -11.72%.
XNCR's FCF Margin % is ranked better than 95.11% of 1044
companies
in the Biotechnology industry
Industry Median: -146.375
vs XNCR: 30.43
Xencor FCF Margin % Historical Data
The historical data trend for Xencor's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xencor's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xencor's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xencor's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Xencor's FCF Margin % falls into.
Xencor FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Xencor's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xencor FCF Margin % Related Terms
Thank you for viewing the detailed overview of Xencor's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XNCR has been successfully added to your 